Molecular Cancer Therapeutics

Table of Contents

February 2014 • Volume 13 • Number 2

Highlights of This Issue 273

REVIEW

275 Targeting Microtubules by Natural Agents for Cancer Therapy
Eiman Mukhtar, Vaqar Mustafa Adhami, and Hasan Mukhtar

SMALL MOLECULE THERAPEUTICS

285 Inhibition of GSK-3 Induces Differentiation and Impaired Glucose Metabolism in Renal Cancer
Krishnendu Pal, Ying Cao, Irina N. Gaisina, Santanu Bhattacharya, Shamit K. Dutta, Enfeng Wang, Hendra Gunosewoyo, Alan P. Kozikowski, Daniel D. Billadeau, and Debabrata Mukhopadhyay

297 Bisphosphonamidate Clodronate Prodrug Exhibits Selective Cytotoxic Activity against Melanoma Cell Lines
Marie R. Webster, Chandrashekhar Kamat, Nick Connis, Ming Zhao, Ashani T. Weeraratna, Michelle A. Rudek, Christine L. Hann, and Caren L. Freel Meyers

307 Selective Inhibition of Pancreatic Ductal Adenocarcinoma Cell Growth by the Mitotic MPS1 Kinase Inhibitor NMS-P715
Roger B. Slee, Brenda R. Grimes, Ruchi Bansal, Jesse Gore, Corinne Blackburn, Lyndsey Brown, Racheal Gasaway, Jaesik Jeong, Jose Victorino, Keith L. March, Ricardo Colombo, Brittney-Shea Herbert, and Murray Korc

316 Inhibition of Insulin-like Growth Factor-Binding Protein-3 Signaling through Sphingosine Kinase-1 Sensitizes Triple-Negative Breast Cancer Cells to EGF Receptor Blockade
Janet L. Martin, Hasanthi C. de Silva, Mike Z. Lin, Carolyn D. Scott, and Robert C. Baxter

329 The Selective Anaplastic Lymphoma Receptor Tyrosine Kinase Inhibitor ASP3026 Induces Tumor Regression and Prolongs Survival in Non–Small Cell Lung Cancer Model Mice
Masamichi Mori, Yoko Ueno, Satoshi Konagai, Hiroshi Fushiki, Itsuro Shimada, Yutaka Kondoh, Rika Saito, Kenichi Mori, Nobuaki Shindou, Takatoshi Soga, Hideki Sakagami, Takashi Furutani, Hitoshi Doihara, Masafumi Kudo, and Sadao Kuromitsu

341 A Naturally Derived Small Molecule Disrupts Ligand-Dependent and Ligand-Independent Androgen Receptor Signaling in Human Prostate Cancer Cells
Karishma S. Amin, Shankar Jagadeesh, Gakul Baishya, Paruchuri G. Rao, Nabin C. Barua, Samir Bhattacharya, and Partha P. Banerjee

353 Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, Chaohua Zhang, Manuel Sequeira, Suqin He, Jim Sang, Richard C. Bates, and David A. Proia

364 Characterization of LY2228820 Dimesylate, a Potent and Selective Inhibitor of p38 MAPK with Antitumor Activity

LARGE MOLECULE THERAPEUTICS

375 Increasing the Antitumor Effect of an EpCAM-Targeting Fusion Toxin by Facile Click PEGylation
Manuel Simon, Nikolas Stefan, Lubor Borsig, Andreas Pluckthun, and Uwe Zangemeister-Wittke

386 Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling
Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab
Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant, and Judy C. Young

Correction: Aerosol Delivery of Urocanic Acid–Modified Chitosan/Programmed Cell Death 4 Complex Regulated Apoptosis, Cell Cycle, and Angiogenesis in Lungs of K-ras Null Mice

ABOUT THE COVER
The ALK/MET inhibitor crizotinib has already shown efficacy in ALK-driven non–small cell lung cancer patients, but the treatment is not curative with rapid acquisition of resistance, which is partly attributable to the gatekeeper-residue mutation L1196M of ALK. Computational modeling suggested that ASP3026, a novel small molecule ALK inhibitor, is well docked with both wild-type and L1196M ALK, and fits more deeply within the ATP-binding pocket of the L1196M form, with the larger side-chain of methionine compared to leucine, than crizotinib. This might explain why ASP3026 showed more potent efficacy against the L1196M mutant within the therapeutic margin compared with crizotinib. For details, see article by Mori and colleagues, on page 329.